32 research outputs found
Indications for late preterm birth, and factors associated with short term maternal and neonatal outcomes at a tertiary care institution
Background: The preterm birth rate is rising mainly because of the marked increase in late preterm deliveries.Objectives: To evaluate the indications for LPTB and the factors associated with the short term maternal and neonatal outcomes.Methods: This retrospective study was conducted at a tertiary health care institution. The study sample included 191 women who delivered between October 2019 to November 2020.Results: The majority (81%) were medically indicated LPTB, and mainly for maternal indications (77%). The most common maternal indication for LPTB was for hypertensive disease of pregnancy (HDP) (82.5%). There was a significant increase in the high care/ ICU admission for maternal indication of LPTB, maternal age < 20 years, and patients with HDP. There was 1 maternal death and 1 neonatal death. 48% of the neonates were admitted to NICU and 53% had neonatal complications. Neonates born by caesarean delivery were more likely to have respiratory complications and be admitted to NICU.Conclusion: These maternal/ neonatal factors should be used to identify patients at risk of adverse maternal and neonataloutcomes.Keywords: Late preterm birth; indications; hypertensive disorder of pregnancy; short term maternal outcomes; short term neonatal outcomes; factors
Remote Ischemic Conditioning Reduces Myocardial Infarct Size in STEMI Patients Treated by Thrombolysis
Correction: Vitamin K Supplementation in Postmenopausal Women with Osteopenia (ECKO Trial): A Randomized Controlled Trial
Recommended from our members
The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism
Increased intake of dietary carbohydrate that is fermented in the colon by the microbiota has been reported to decrease body weight, although the mechanism remains unclear. Here we use in vivo11C-acetate and PET-CT scanning to show that colonic acetate crosses the bloodābrain barrier and is taken up by the brain. Intraperitoneal acetate results in appetite suppression and hypothalamic neuronal activation patterning. We also show that acetate administration is associated with activation of acetyl-CoA carboxylase and changes in the expression profiles of regulatory neuropeptides that favour appetite suppression. Furthermore, we demonstrate through 13C high-resolution magic-angle-spinning that 13C acetate from fermentation of 13C-labelled carbohydrate in the colon increases hypothalamic 13C acetate above baseline levels. Hypothalamic 13C acetate regionally increases the 13C labelling of the glutamateāglutamine and GABA neuroglial cycles, with hypothalamic 13C lactate reaching higher levels than the āremaining brainā. These observations suggest that acetate has a direct role in central appetite regulation
Acetate Causes Alcohol Hangover Headache in Rats
Background: The mechanism of veisalgia cephalgia or hangover headache is unknown. Despite a lack of mechanistic studies, there are a number of theories positing congeners, dehydration, or the ethanol metabolite acetaldehyde as causes of hangover headache. Methods: We used a chronic headache model to examine how pure ethanol produces increased sensitivity for nociceptive behaviors in normally hydrated rats. Results: Ethanol initially decreased sensitivity to mechanical stimuli on the face (analgesia), followed 4 to 6 hours later by inflammatory pain. Inhibiting alcohol dehydrogenase extended the analgesia whereas inhibiting aldehyde dehydrogenase decreased analgesia. Neither treatment had nociceptive effects. Direct administration of acetate increased nociceptive behaviors suggesting that acetate, not acetaldehyde, accumulation results in hangover-like hypersensitivity in our model. Since adenosine accumulation is a result of acetate formation, we administered an adenosine antagonist that blocked hypersensitivity. Discussion: Our study shows that acetate contributes to hangover headache. These findings provide insight into the mechanism of hangover headache and the mechanism of headache induction
A Prevalent Variant in PPP1R3A Impairs Glycogen Synthesis and Reduces Muscle Glycogen Content in Humans and Mice (vol 5, pg e27, 2008)
Background: Stored glycogen is an important source of energy for skeletal muscle. Human genetic disorders primarily affecting skeletal muscle glycogen turnover are well-recognised, but rare. We previously reported that a frameshift/premature stop mutation in PPP1R3A, the gene encoding RGL, a key regulator of muscle glycogen metabolism, was present in 1.36% of participants from a population of white individuals in the UK. However, the functional implications of the mutation were not known. The objective of this study was to characterise the molecular and physiological consequences of this genetic variant.
Methods and Findings: In this study we found a similar prevalence of the variant in an independent UK white population of 744 participants (1.46%) and, using in vivo 13C magnetic resonance spectroscopy studies, demonstrate that human carriers (n = 6) of the variant have low basal (65% lower, p = 0.002) and postprandial muscle glycogen levels. Mice engineered to express the equivalent mutation had similarly decreased muscle glycogen levels (40% lower in heterozygous knock-in mice, p < 0.05). In muscle tissue from these mice, failure of the truncated mutant to bind glycogen and colocalize with glycogen synthase (GS) decreased GS and increased glycogen phosphorylase activity states, which account for the decreased glycogen content.
Conclusions: Thus, PPP1R3A C1984ĪAG (stop codon 668) is, to our knowledge, the first prevalent mutation described that directly impairs glycogen synthesis and decreases glycogen levels in human skeletal muscle. The fact that it is present in ~1 in 70 UK whites increases the potential biomedical relevance of these observations
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; pā=ā0.40). There was no significant effect of DMF on any secondary outcome
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; pā=ā0.40). There was no significant effect of DMF on any secondary outcome
In vivo 1H MR spectroscopy with Jārefocusing
Purpose
The goal of this study was to propose a novel localized proton MR spectroscopy (MRS) sequence that reduces signal loss due to Jāmodulation in the rat brain in vivo.
Methods
SpragueāDawley rats were studied at 9.4 T. A semiāLASER sequence with evenly distributed echoātime (TE) was used, and a 90Ā° Jārefocusing pulse was inserted at TE/2. Proton spectra were acquired at two TEs (30 and 68 ms), with and without the Jārefocused pulse. Data were processed in MATLAB and quantified with LCModel.
Results
The Jārefocused spectrum acquired at TE = 30 ms did not show any signal losses due to Jāmodulation and had comparable spectral pattern to the one acquired with semiāLASER using the minimum achievable TE. Higher signal amplitudes for glutamine, Ī³āaminobutyric acid and glutathione led to more reliable quantification precision for these metabolites. The refocused signal intensities at TE = 68 ms were also unaffected by Jāmodulation but were smaller than the signals at TE = 30 ms mainly due to transverse T2 relaxation of metabolites.
Conclusion
The proposed localized MRS sequence will be beneficial in both animal and human MRS studies when using ultraāshort TE is not possible while also providing more reliable quantification precision for Jācoupled metabolites